

# Can we predict the phenotype of an individual from DNA?

Edith Le Floch DRF/ Institut de biologie François Jacob/ Centre National de Recherche en Génomique Humaine





## How to predict Alzheimer's Disease from DNA?

#### Alzheimer's Disease:

- A neurodegenerative disease associated with cognitive disorders and memory loss
- Prevalence: almost 20% in people over 80

#### Some genetic origins:

- Common form caused at ~75% by genetic factors
- But the known causal genes account only for 8% (main gene APOE accounts for 6%)





## How to predict Alzheimer's Disease from DNA?

#### Alzheimer's Disease:

- A neurodegenerative disease associated with cognitive disorders and memory loss
- Prevalence: almost 20% in people over 80

#### Some genetic origins:

- Common form caused at ~75% by genetic factors
- But the known causal genes account only for 8% (main gene APOE accounts for 6%)





# Alzheimer's Disease Neuroimaging Initiative (ADNI)

- Clinical information on 809 individuals:
  - 188 patients with Alzheimer's Disease (AD)
  - 393 patients with Mild Cognitive Impairment (MCI)
  - 228 controls
- Genetic Data available
- Brain imaging data (MRI) also available

# How to predict the patient/control status from DNA?





#### Part 1 : A few notions in Genetics

#### Part 2: The univariate approach

2.1 Genotyping data2.2 Sequencing data

#### Part 3: The multivariate approach (machine learning)

3.1 Sequencing data3.2 Genotyping data





# Part 1: A few notions in Genetics



#### Human genome



EN GÉNOMIQUE HUMAINI

- 22 pairs of homologous chromosomes + X Y
- 2 identical chromatids per chromosome
- 2 complementary strands per chromatid
- Each strand: sequence of nuceotides (Adenine, Thymine, Cytosine and Guanine)
- 3 billion base pairs
- About 2% of DNA coding for proteins: 25 000 genes



# Single Nucleotide Polymorphisms (SNPs) 1/2

- SNP: position on the genome where a single nucleotide varies in the population (>1% of individuals)
  → due to an ancestral mutation
- Main form of DNA variability in the population
  (about 30 million SNPs)
- About 3-4 million single nucleotide differences between 2 individuals
- Usually only **two possible alleles for a SNP:** one major (e.g. A) and one minor (e.g. G)
- The genotype of an individual is defined by considering the pair of homologous chromosomes:
   3 possibilities (e.g. AA, AG or GG)

 $\rightarrow$  often coded as the **number of minor alleles**: 0 (AA), 1 (AG) or 2 (GG)









# Single Nucleotide Polymorphisms (SNPs) 2/2



SNPs may be located :

- inside a gene:
  - in an **exon** (coding for the protein) : synonymous or not
  - in an **intron** (non-coding)
- outside a gene



• LD: non-random association of alleles between two SNPs  $\rightarrow$  often due to physical linkage (*ie* SNPs on the same chromosome)



- $\rightarrow$  The 2 SNPs transmitted together trough generations
- **Recombination** between homologous chromosomes during meiosis

 $\rightarrow$  Probability of recombination increases (and thus LD decreases) with the distance between the 2 SNPs



# Linkage Disequilibrium (LD) 2/3

**Meiosis : formation of** 

reproductive cells (gametes)







- Non-homogeneous recombination between homologous chromosomes during meiosis: hot spots of recombination
  - $\rightarrow$  LD blocks





#### **Genetic diseases**

#### Monogenic (Mendelian) diseases:

- Caused by one single gene
- High effect (often lethal)
- Rare mutations (due to genetic selection)

#### Polygenic (complex) disease:

- Caused by several genes (not the same in every patient)
- Moderate effect
- Common polymorphisms
- $\rightarrow$  The common type of Alzheimer's disease in a complex disease





- Not the whole genome sequence is observed
- Only some of the known SNPs all over the genome
- **1 million** SNPs on common chips today
- **Mainly common SNPs** (>5% in the population)
- Enough to capture most of the common genetic variability and to guess all other SNPs by knowing LD





- The whole genome is sequenced (3 billion bases) for each individual
- Chromosomes not sequenced in one piece:
  Short "reads" of about 100 nucleotides are sequenced
- **Bioinformatics tools needed** to reconstruct the whole sequence:
  - Each read is aligned on a reference sequence
  - Variations from the reference are identified (e.g. SNPs, SNVs)
  - Only variations from the reference are stored in the final file (3-4 million SNPs/SNVs per individual)
- Each nucleotide is sequenced about 30 times to avoid errors
  CNRGH

EN GÉNOMIQUE HUMAINE

### **Cost of Whole Genome Sequencing**





# Part 2: The univariate approach







# Part 2.1: The univariate approach on ADNI genotyping data





# Alzheimer's Disease Neuroimaging Initiative Genotyping data

- 809 individuals:
  - 188 Alzheimer's Disease (AD)
  - 393 Mild Cognitive Impairment (MCI)
  - 228 controls

 The 809 individuals were genotyped with SNP array with 2.5 million SNPs





#### Univariate approach:

- Test for the association of each SNP (with the phenotype) independently
- If the phenotype is disease (case) / not disease (control):
  Is the distribution of the 3 genotypes the same for cases and controls?

For example for a SNP with two possible alleles A and T:

	Cases	Controls
AA	20	10
AT	40	66
тт	75	163

 $\rightarrow$  p-value of a **Chi-square test** = 0.007 but many tests (= nb SNPs) !!



#### **Genotypic test:**

- The most general
- Not very powerful on average to detect moderate associations (higher nb of degrees of freedom)

	Cases	Controls
AA	20	10
AT	40	66
тт	75	163

#### Allelic test:

- Assumes the 2 alleles of an individual are independent (Hardy-Weinberg)
- Assumes additive effects of alleles
- Powerful in most cases

		Cases	Controls
	Minor allele A	20*2+40=80	10*2+66=86
	Major allele T	75*2*40=190	163*2+66=392



- If the phenotype (y) is quantitative  $\rightarrow$  simple linear regression
- Like for case/control studies, an additive model is usually used:

 $y = \beta_0 + \beta \times \#$ minor alleles



# P-value correction in Genome-Wide Association Studies (GWAS)

#### "Manhattan plot" of the p-values of the SNPs along the genome:



• Bonferroni correction commonly used to correct for multiple tests:

1 million SNPs on common chips

 $\rightarrow$  genome-wide significance threshold: 5\*10<sup>-2</sup> / 10<sup>6</sup> = 5\*10<sup>-8</sup>





- The test will be more powerful to detect an association:
  - with high sample size (often 10s of 1000s of individuals)
  - with frequent polymorphisms
  - with strong effects



#### DE LA RECHERCHE À L'INDUSTR

#### **Population structure within Europe**

**Principal component analysis** on 197,146 SNPs (coded 0, 1 or 2) in 1387 individuals

 $\rightarrow$  when plotting the two first principal components, the map of Europe appears!

- $\rightarrow$  even possible to distinguish between :
- French-speaking Swiss
- German-speaking Swiss
- Italian-speaking Swiss



J Novembre et al. Nature, 1-4 (2008)





→ Alleles specific to Pop. 1 artificially associated with the disease!



From lectures by Timothy Thornton



• For a quantitative trait:

EN GÉNOMIQUE HUMAIN

If the 2 populations have different means (due to sampling bias, to different lifestyles)



Histogram of Trait Values

 $\rightarrow$  Alleles specific to 1 population **artificially associated** with the trait!

From lectures by Timothy Thornton



- Comparison of Alzheimer patients (188) versus others (621) on the 2.5 million SNPs
- 3 variants with a significant p-value after Bonferroni correction  $(p<2*10^{-8})$  with  $\chi^2$  test or Fisher exact test
  - 1 in APOE intron and in regulatory region (p=1.4\*10<sup>-12</sup>)
  - 2 in intergenic regions near APOE ( $p=3*10^{-13}$  and  $p=6*10^{-14}$ )
- Associated variants are frequent (Minor Allele Freq. 20-40%)





- GWAS on genotyping data **have identified many SNPs** (14000) significantly associated with more than 1500 phenotypes
- But they only explain a small portion of the phenotypic variance (8 % for Alzheimer's disease instead of 75%!)
   → Missing heritability
- Many possible reasons for missing heritability:
  - rare variants
  - interaction effects between variants
  - many small effects that cannot be detected with current sample sizes



DE LA RECHERCHE À L'INDUSTRI

## Global results of GWAS on diseases



#### **Allele Frequency**

# Contract Con



#### Allele Frequency

#### DE LA RECHERCHE À L'INDUSTRIE

### **Global results of GWAS on diseases**



#### Allele Frequency

#### DE LA RECHERCHE À L'INDUSTRIE

### **Global results of GWAS on diseases**



#### **Allele Frequency**





# Part 2.2: The univariate approach on ADNI sequencing data





# Alzheimer's Disease Neuroimaging Initiative Sequencing data

- **809 individuals** with Whole Genome Sequencing data
  - 188 Alzheimer's Disease (AD)
  - 393 Mild Cognitive Impairment (MCI)
  - 228 controls
- ~4 million variants per individual
  → ~60 million variants for all individuals
- 63% of the SNVs with good quality  $\rightarrow$  ~40 million variants of good quality





Among the 40 million variants of good quality :

- 46% of variants are specific to only 1 individual: 18 400 000 variants
- $\Rightarrow$  <1% of the variants of an individual are specific to this individual : 20000-25000 variants
- 2% of the variants located in genes (coding for proteins)
- 15% of the variants are annotated by epigenetic markers seen in brain cells (DNA regions not necessarily coding for proteins but influencing the transcription into RNA)





- Comparison of AD patients (188) versus others (621)
- 16 SNPs with a significant p-value after Bonferroni correction (χ<sup>2</sup> test/Fisher's exact test) : 10<sup>-18</sup> <p< 10<sup>-9</sup> in the APOE region (36kb)
- Top associated SNP:

rs429358 (non-synonymous) :  $p=5*10^{-18}$ One of the 2 SNPs of APOE4 allele

• Associated variants are frequent (MAF 20-40%)



# DE LA RECHERCHE À L'INDUSTRIE

#### LD structure between the significant SNPs





APOE region on chromosome 19 rs429358 (missense) :  $p=5*10^{-18}$ One of the 2 SNPs of APO $\epsilon$ 4 allele

#### PCDH11X on chromosome X

rs2750788 (intron) : p=4\*10<sup>-8</sup> Already associated with Alzheimer's Disease

#### LINGO2 on chromosome 9

rs2578253 (intron) : p=5\*10<sup>-8</sup> Already associated with Parkinson's Disease

#### ATP11C on chromosome X

rs2485724 (intron) : p=2.5\*10<sup>-8</sup>



- Univariate GWAS methods (linear regression, chi-square) may be applied BUT:
  - much more multiple comparisons (tens of millions)
  - very low power to detect association for rare variants

- **More individuals needed** but expensive (>1000\$ per individual)
- Statistical methods need to be adapted by collapsing nearby variants: Region-based analysis (multivariate approach)

 $\rightarrow$  stronger signals and fewer tests (20000-25000 genes)





# Part 2: The multivariate approach







# Part 3.1: The multivariate approach on sequencing data



#### Multiple regression model :

- *p* variants in **a certain region** (e.g. a gene)
- **Genotypes** of individual  $i : X_i (1 \times p)$ , coded 0, 1 or 2
- **Covariates** of individual i :  $Z_i$  (1 × k) such as age, sex, pop. structure
- For a **case/control** (1/0) phenotype  $Y_i$ :

$$logit(p_i) = ln\left(\frac{p_i}{1-p_i}\right) = \alpha_0 + \mathbf{Z}_i \boldsymbol{\alpha} + \mathbf{X}_i \boldsymbol{\beta}$$
 with  $p_i = P(Y_i = 1 | \mathbf{X}_i, \mathbf{Z}_i)$ 

• Test of no region effect:  $H_0: \boldsymbol{\beta} = (\beta_1, ..., \beta_p)^T = \mathbf{0}$ 





• Recall of the multiple regression model:

 $E(Y_i | \boldsymbol{X}_i, \boldsymbol{Z}_i) / logit(p_i) = \alpha_0 + \boldsymbol{Z}_i \boldsymbol{\alpha} + \boldsymbol{X}_i \boldsymbol{\beta}$ 

• Assume random effects:

 $\beta_i \sim distribution (0, w_i^2 \tau)$ 

where  $w_j^2$  is an optional weight for variant *j* (higher for rare variants)

• Test of no region effect:

$$\mathsf{H}_0: \beta_1 = \dots = \beta_p = 0 \iff \tau = 0$$





SKAT tests the association of a group of variants (a gene) with the phenotype, assuming additive effects of variants:

- SKAT on each full gene: no significant results after correction even on candidate genes
- SKAT on each gene with exons only: 2 significant genes (p=10<sup>-6</sup>) after correction APOE and SORBS3 (already associated with Alzheimer's disease)







# Part 3.2: The multivariate approach on genotyping data





## Heritabilty on genotyping data to predict Alzheimer's disease

#### Heritability on SNPs:

Same model as SKAT (logistic regression with additive random effects) but on genome-wide common SNPs

#### **Results obtained on Alzheimer's disease genotyping data:**

- with 809 individuals (188 AD/621 controls) and 2.5M SNPs from ADNI : heritability of 10% but high variance
- with 9900 individuals (2400 AD/7500 controls) and 500K SNPs from CNRGH : heritability of 75%!



# Results of multivariate methods on genotyping data to predict Alzheimer's disease

Results obtained on Alzheimer's disease genotyping data using AdaBoost (trees) or Random forests:

- with 809 individuals (188 AD/621 controls) and 2.5M SNPs from ADNI
- with 9900 individuals (2400 AD/7500 controls) and 500K SNPs from CNRGH

Data set	Accuracy AD	Accuracy controls	Global accuracy
ADNI genotyping data	6%	100%	63%
CNRGH genotyping data	46%	93%	82%





 At the gene level with sequencing data, significant association for APOE and SORBS3 only and driven by common SNPs

 At the whole genome level with genotyping data, classification algorithms failed on ADNI data

• Improvement when much more samples and fewer SNPs





- At the gene/SNP level, a few significant associations and mainly on common SNPs (no great improvement with sequencing data and rare variants yet)
- At the whole genome level multivariate algorithms are promising on genotyping with common SNPs data suggesting cummulative effects of many SNPs
- But we need many samples! A lot are coming.... (even companies like Google)
- We need to integrate other sources of omics data (RNA, proteins, DNA methylation, DNA 3D structure, ...) and biological knowledge (such as gene networks)

